Plandai Biotechnology: A Natural Fit Into the Marijuana Industry
March 03 2014 - 9:00AM
Marketwired
Plandai Biotechnology: A Natural Fit Into the Marijuana Industry
NEW YORK, NY--(Marketwired - Mar 3, 2014) - Plandaí
Biotechnology (OTCQB: PLPL) has a strong executive team in place, a
well thought out business plan, and now it's time for the company
to make its products the star. These products include Plandaí's
Phytofare™ botanical extracts such as its Green Tea Catechin
Complex and the Limonoid Glycoside Complex, as well as a line of
Diego Pellicer® medical cannabis products. It is the latter could
make the company a leader in the marijuana industry.
Plandaí entered the marijuana space in November 2013, and since
that time, the biotech has moved quickly to develop its Phytofare™
cannabis extracts, it has also found a branding partner in Diego
Pellicer, Inc., and it named former Microsoft executive Jamen
Shively as the company's Vice President of Global Marketing to
build and market the brand of cannabis extracts.
None of this should be a surprise however, as Plandaí very well
could be the most natural fit of any publicly traded company into
the marijuana arena. After all, Plandaí is a producer of highly
bioavailable plant extracts for the health, wellness,
nutraceutical, and pharmaceutical industries, so adding an
additional plant (cannabis) for development into the lineup of
botanicals the company already works with (green tea, limonoids)
only enhances its product offerings.
But, it doesn't stop there. What sets Plandaí apart from many
other companies working with botanicals is its hydrodynamic
extraction process that allows the company to use science to
achieve the most bioavailability from those plants.
While tetrahydrocannabinol (THC) has demonstrated the ability to
reduce tumors and slow the progression of Alzheimer's, it is the
second largest constituent of cannabis, cannabidiol (CBD), which
doesn't have psychoactive properties that will likely be the
primary focus of Plandaí's testing. A number of recent studies that
show the healing and treatment benefits of cannabinoids in diseases
like diabetes, ALS, Crohn's disease, multiple sclerosis, among
others favor a biotech company like Plandaí that will engage in its
own studies using cannabis.
About Stock Market Media Group SMMG is a full service IR firm
specializing in Research and Content Development. It offers a
platform for corporate stories to unfold through the media with
Reports, Interviews and Articles. SMMG is compensated up to $650 by
a third party for each article written. For more information and to
read disclaimers and disclosures:
www.stockmarketmediagroup.com/disclaimer.
Contact: Stock Market Media Group Email Contact
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Jul 2023 to Jul 2024